Technology

DURECT

$2.45
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (+1.35%) Today
+$0.20 (+8.89%) As of 11:09 AM UTC after-hours

Why Robinhood?

You can buy or sell DURECT and other stocks, options, and ETFs commission-free!

About DRRX

DURECT Corporation Common Stock, also called DURECT, is a biopharmaceutical company. It engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA. The listed name for DRRX is DURECT Corporation Common Stock.

CEO
James E. Brown
Employees
90
Headquarters
Cupertino, California
Founded
1998
Market Cap
453.03M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
896.75K
High Today
$2.25
Low Today
$2.15
Open Price
$2.21
Volume
883.20K
52 Week High
$2.96
52 Week Low
$0.9502

Collections

DRRX Earnings

-$0.05
-$0.01
$0.03
$0.07
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 3, After Hours

You May Also Like

SE
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure